← 返回

DADA 增强 CD8(+) T 细胞干性以改善抗肿瘤免疫和免疫治疗疗效

英文原题:DADA Enhances CD8(+) T Cell Stemness to Improve Anti-Tumor Immunity and Immunotherapy Efficacy.

查看英文原题

DADA Enhances CD8(+) T Cell Stemness to Improve Anti-Tumor Immunity and Immunotherapy Efficacy.

PubMed 2026/02/27(内容时间) Adv Sci (Weinh) Q1 · IF 14.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

祖细胞耗竭CD8+ T(Tpex)细胞最近被鉴定为一种干细胞样T细胞亚群,介导持久的抗肿瘤免疫应答,并且是对免疫治疗有反应的关键细胞群体。本研究表明,二异丙胺二氯乙酸(DADA)促进CD8+ T细胞介导的抗肿瘤免疫,并促进Tpex细胞在肿瘤微环境中的积累。机制上,DADA通过抑制丙酮酸脱氢酶激酶促进丙酮酸向Acetyl-CoA的转化。这一过程导致氧化磷酸化(OXPHOS)和线粒体适应性增强,从而增强CD8+ T细胞的干性。用DADA治疗小鼠提高了PD-1阻断的疗效。此外,在体外扩增CAR-T 细胞时添加DADA可赋予其干性特征,有助于提高抗肿瘤疗效。总之,本研究阐明了DADA介导的CD8+ T细胞代谢重编程如何增强其干性,强调了其在抗肿瘤治疗中的潜力。

展开英文摘要原文

Progenitor exhausted CD8 + T (Tpex) cells have recently been identified as a stem-like T cell subset that mediates durable anti-tumor immune responses and represents a pivotal population responsive to immunotherapies.

Here, it is demonstrated that diisopropylamine dichloroacetate (DADA) facilitates CD8 + T cell-mediated anti-tumor immunity and promotes Tpex cells accumulation in the tumor microenvironment.

Mechanistically, DADA promotes the conversion from pyruvate to Acetyl-CoA by inhibiting pyruvate dehydrogenase kinase. This process leads to increased oxidative phosphorylation (OXPHOS) and mitochondrial fitness, thereby enhancing CD8 + T cells stemness. Treatment of mice with DADA improves the efficacy of PD-1 blockade.

Furthermore, the in vitro expansion of chimeric antigen receptor (CAR)-T cells supplemented with DADA confers them with stemness characteristics, contributing to improved anti-tumor efficacy. Collectively, this study illustrates how DADA-mediated metabolic reprogramming in CD8 + T cell enhances their stemness, underscoring its potential for anti-tumor therapy.

论文信息

作者
Bi M、Li F、Jiang H、Gu L、Sun M、Lu K、Liu P、Xie R
单位
Department of Clinical Laboratory, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.China
期刊
Advanced science (Weinheim, Baden-Wurttemberg, Germany)2026 May
原文标识
PubMed 41758776 · DOI 10.1002/advs.202519765